Cited by 2,785Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and ProtectionMetal-Catalyzed Oxygenation Mechanisms

The DOI matches its Crossref record.

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Shimada, T, Yamazaki, H, Mimura, M, Inui, Y, Guengerich, F P·1994·The Journal of Pharmacology and Experimental Therapeutics

DOI 10.1016/s0022-3565(25)22379-5

Open this paper in CoChat — free account

Abstract

Interindividual variations in the level and activity of cytochrome P-450 enzymes were investigated in the liver microsomes of 30 Japanese and 30 Caucasian patients. The P-450 enzymes used in this study included P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A, and the monooxygenase activities determined were 13 typical P-450 substrates and 9 procarcinogens. Although the total P-450 content was higher in Caucasian (mean, 0.43 nmol/mg of protein) than in Japanese populations (mean, 0.26 nmol/mg of protein), the relative levels (percent of total P-450) of individual forms of P-450 determined immunochemically were not very different except that P-450 2A6 and 2B6 levels were higher in the Caucasians. About 70% of liver P-450 could be accounted for by P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A proteins, and P-450 3A (about 30% of total P-450) and 2C (about 20%) enzymes were found to be the major forms. Considerable levels of P-450 1A2 (about 13%) and 2E1 (about 7%) could be determined, whereas the P-450 2A6 (about 4%), 2D6 (about 2%) and 2B6 (< 1%) were the minor P-450 forms. Differences in some of the P-450 1A2-, 2A6-, 2D6-, 2E1- and 3A4-dependent activities were observed in Japanese and Caucasian populations. No clear sex-related differences in individual P-450 contents and drug- and carcinogen-metabolizing activities were detected in 60 human samples, except that P-450 1A2-dependent activities were found to be higher in mean than in women in the Caucasian population only. A single neonate sample tended to be lower in P-450 1A2-, 2A6- and 2E1-dependent activities. In contrast to rat counterparts, we could not detect apparent developmental changes in P-450 content and activity in humans between 12 and 73 years old. Thus, the results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis.

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)22379-5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 1,005

Involvement of Cytochrome P450 in Reactive Oxygen Species Formation and Cancer
Hrycay, E. G., & Bandiera, S. M. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2015.03.003 · Cited by 234
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*
Wrighton, S. A., Schuetz, E. G., Thummel, K. E., Shen, D. D., Korzekwa, K. R., & Watkins, P. B. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102338 · Cited by 214
Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man
Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A. D., & El-Sankary, W. (2002) · Xenobiotica · doi:10.1080/00498250110102674 · Cited by 209
“There is a substantial interindividual variation in CYP3A4 expression in man (10±100-fold; Shimada et al. 1994, Watkins 1994), but the molecular basis for this variation is not fully understood at present, and may possibly be attributed to factors of both environmental and/or genetic origin.”
Background
Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis
Achour, B., Barber, J., & Rostami-Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058834 · Cited by 212
Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle
Evans, M., & Rees, A. (2002) · Drug Safety · doi:10.2165/00002018-200225090-00004 · Cited by 211
Influence of Diet and Nutritional Status on Drug Metabolism
Walter‐Sack, I., & Klotz, U. E. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00004 · Cited by 209
Multiple forms of human P450 expressed in Saccharomyces cerevisiae
Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y., & Funae, Y. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00052-4 · Cited by 207
Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin
Svensson, & Ashton (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00044.x · Cited by 207
Seville orange juice-felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins
Malhotra, S. V. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113185 · Cited by 207
A review on photocatalytic application of g-C3N4/semiconductor (CNS) nanocomposites towards the erasure of dyeing wastewater
Lam, S., Sin, J., & Mohamed, A. R. (2016) · Materials Science in Semiconductor Processing · doi:10.1016/j.mssp.2016.02.019 · Cited by 206
Ontogeny of drug metabolizing enzymes in the neonate
Blake, M. J., Castro, L., Leeder, J. S., & Kearns, G. L. (2005) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2004.11.001 · Cited by 200
Cytochrome P450 2E1: its clinical and toxicological role
Tanaka, Terada, & Misawa (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00282.x · Cited by 203
“The effect of aniline (91) and organosulphur compounds (92), including allylsulphide (AS), allylmercaptan (AM) and allylmethylsulphide (AMS), on the expression of CYP2E1 was examined in rats.”
Background
The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine
Bolt, H. M., Roos, P. H., & Thier, R. (2003) · International Archives of Occupational and Environmental Health · doi:10.1007/s00420-002-0407-4 · Cited by 203
Role of drug metabolism in drug discovery and development
Kumar, G. N., & Surapaneni, S. (2001) · Medicinal Research Reviews · doi:10.1002/med.1016 · Cited by 201
Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches
Venkatakrishnan, K., Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13680-x · Cited by 200
Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs
Kreth, K.-P., Kovar, K., Schwab, M. G., & Zanger, U. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00284-7 · Cited by 198
“CYP3A4, on the other hand, is the predominant liver P450 isozyme, and its expression levels in human liver are approximately 2- to 5-fold higher than those of CYP1A2 [29].”
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
Stingl, J., Brockmöller, J., & Viviani, R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.42 · Cited by 200
Sex-specific differences in CYP450 isoforms in humans
Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199
Drugs as CYP3A Probes, Inducers, and Inhibitors
Liu, Y., Hao, H., Liu, C., Wang, G., & Xie, H. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701690374 · Cited by 197
“In fact, CYP3A (mainly CYP3A4 and CYP3A5) is the greatest piece of the human liver and intestine P450 “pie,” accounting for approximately 40% and 80% of total P450 content, respectively (Paine et al., 2006; Shimada et al., 1994).”
Background
Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450
Muto, S., Fujita, K., Yamazaki, Y., et al. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00204-4 · Cited by 195
Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance
Teh, L. K., & Bertilsson, L. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-121 · Cited by 193
Markers of genetic susceptibility in human environmental hygiene and toxicology: The role of selected CYP, NAT and GST genes
Thier, R., Brüning, T., Roos, P. H., Rihs, H., Golka, K., Ko, Y. D., & Bolt, H. M. (2003) · International Journal of Hygiene and Environmental Health · doi:10.1078/1438-4639-00209 · Cited by 195
Drug–drug interactions of silymarin on the perspective of pharmacokinetics
Wu, J.-W., Lin, L.-C., & Tsai, T. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.10.036 · Cited by 191
Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.
Subrahmanyam, V. V., Renwick, A. B., Walters, D. G., Young, P. J., Price, R. J., Tonelli, A. P., & Lake, B. G. (2001) · PubMed · Cited by 190
Metabolism and Transport of Oxazaphosphorines and the Clinical Implications
Zhang, J., Tian, Q., Chan, S. Y., et al. (2005) · Drug Metabolism Reviews · doi:10.1080/03602530500364023 · Cited by 190
“In addition, there is a significant variation in the hepatic expression of CYP3A4 based on in vitro (35–100-fold) studies using human liver bank (Shimada et al., 1994) and in vivo (20–50-fold) using probe drugs such as erythromycin (Watkins, 1994), midazolam (Thummel et al., 1994), and alfentanil…”
Background
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
Doan, J., Zakrzewski-Jakubiak, H., Roy, J. J., Turgeon, J., & Tannenbaum, C. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r621 · Cited by 189
“Common reasons for taking action to modify the risk of a potentially relevant CYP-mediated DDI were (1) when therapeutic failure or increased toxicity from one of the interacting substrates was thought to underlie the condition that precipitated the patient’s admission (eg, uncontrolled neuropsychiatric symptoms in a…”
Background
Adsorption of hazardous dyes on functionalized multiwalled carbon nanotubes in single and binary systems: Experimental study and physicochemical interpretation of the adsorption mechanism
Li, Z., Sellaoui, L., Franco, D. S. P., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.124467 · Cited by 188
Children versus adults: pharmacokinetic and adverse-effect differences
Anderson, G. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.43.s.3.5.x · Cited by 187
“Eight primary isozymes are involved in the hepatic metabolism of most drugs: CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (8,9).”
Background
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nussler, A. K., Neuhaus, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202345200 · Cited by 185
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*
Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., & Echizen, H. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90103-5 · Cited by 183
In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse.
Chauret, N., Gauthier, A., Martin, J., et al. (1997) · PubMed · Cited by 183
Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products
Appiah‐Opong, R., Commandeur, J. N. M., van Vugt-Lussenburg, B., & Vermeulen, N. P. E. (2007) · Toxicology · doi:10.1016/j.tox.2007.03.007 · Cited by 178
Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective
Chen, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.010 · Cited by 186
Increased transcriptional activity of the CYP3A4*1B promoter variant
Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, F. F., & Rebbeck, T. R. (2003) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10199 · Cited by 183
“CYP3A4 is involved in the metabolism of numerous compounds in adult human liver, and accounts for 30–60% of total liver cytochrome P-450 protein [Gonzalez and Idle, 1994; Shimada et al., 1994].”
Background
Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects
Cherniakov, I., Domb, A. J., & Hoffman, A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999038 · Cited by 187
“This traditional point of view was based on the observation that the protein levels of drug-metabolizing enzymes in the small intestine were found to be generally significantly lower than those in the liver [46,47].”
Background
Novel detection assay by PCR???RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese population
Fukuen, S., Fukuda, T., Maune, H., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00009 · Cited by 180
Methadone N‐demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4
Foster, D. J. R., Somogyi, A. A., & Bochner, F. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00921.x · Cited by 176
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
Tracy, T. S., Korzekwa, K. R., Gonzalez, F. J., et al. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00923.x · Cited by 180
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lindley, C. M., Yan, B., Negishi, M., & LeCluyse, E. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.348 · Cited by 179
“%) of total hepatic cytochrome P450 content and to play an insignificant role in human drug metabolism (Shimada et al., 1994).”
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C. A., Andersson, T. B., Ingelman‐Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
Ekins, S., VandenBranden, M. R., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., & Wrighton, S. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37719-5 · Cited by 178
Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva
Tseng, H., Hseu, T., Buhler, D. R., et al. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.019 · Cited by 178
In Vitro Metabolism of Pyrethroid Pesticides by Rat and Human Hepatic Microsomes and Cytochrome P450 Isoforms
Scollon, E. J., Starr, J. M., Godin, S., DeVito, M. J., & Hughes, M. F. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022343 · Cited by 178
“In human liver, approximately 20 and 30% of total P450 is composed of the CYP2C and CYP3A families, respectively (Shimada et al., 1994).”
Background
Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants
Ginsberg, G., Hattis, D. B., & Sonawane, B. R. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.10.010 · Cited by 178
THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*
Ekins, S., & Wrighton, S. A. (1999) · Drug Metabolism Reviews · doi:10.1081/dmr-100101942 · Cited by 176
O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells Effect of Metabolic Inhibitors and SSRI Antidepressants
Fogelman, S. M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00113-4 · Cited by 176
“The method developed by Crespi (1995) attempts to quantify the contribution of an cDNA-expressed enzyme to the overall metabolism of a substrate by multiplying the intrinsic clearance via a specific pathway by the relative abundance of the enzyme in human liver (Shimada et al. 1994; Venkatakrishnan et al. 1998b).”
BackgroundMethod
Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*
Engel, G., Hofmann, U., Heidemann, H. T., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90001-6 · Cited by 176
Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes
Yamazaki, H., Inoue, K., Chiba, K., et al. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 174
Self-citation
Compound lipophilicity for substrate binding to human P450s in drug metabolism
Lewis, D. F. V., Jacobs, M. N., & Dickins, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03115-0 · Cited by 175
Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans
Shimada, T., Mimura, M., Inoue, K., Nakamura, S.-I., Oda, H., Ohmori, S., & Yamazaki, H. (1997) · Archives of Toxicology · doi:10.1007/s002040050403 · Cited by 174
Self-citation
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
Parikh, S., Ouédraogo, J., Goldstein, J. A., Rosenthal, P. J., & Kroetz, D. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100122 · Cited by 171
The Emerging Role of Cytochrome P450 3A in Psychopharmacology
Ketter, T. A., Flockhart, D. A., Post, R. M., Denicoff, K. D., Pazzaglia, P. J., Marangell, L. B., George, M. S., & Callahan, A. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00002 · Cited by 168
Midazolam and Triazolam Biotransformation in Mouse and Human Liver Microsomes: Relative Contribution of CYP3A and CYP2C Isoforms
Perloff, M. D., Moltke, L. L., Court, M. H., Kotegawa, T., Shader, R. I., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35332-7 · Cited by 169
“greatly from person to person (Shimada et al., 1994), Vmax and intrinsic clearance values obtained in this study may be”
Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada, T., Gillam, E. M. J., Sutter, T. R., et al. (1997) · PubMed · Cited by 169
Self-citation
An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials
Parkinson, A. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400107 · Cited by 169
“Without exception, the levels and activity of each P450 enzyme have been shown to vary from one individual to the next, due to environmental and/or genetic factors (15, 27).”
Background
Pharmacokinetics and Pharmacodynamic Changes Associated with Aging and Implications for Drug Therapy
Sera, L., & McPherson, M. L. (2012) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2012.01.007 · Cited by 166
Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics
Achour, B., Russell, M. R., Barber, J., & Rostami‐Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055632 · Cited by 169
“Nevertheless, immunoquantification methods have been used extensively to measure the abundance of cytochrome P450 enzymes (Shimada et al., 1994; Yamazaki et al., 1997; Tateishi et al., 1999; Lin et al., 2002).”
BackgroundMethod
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia
Basile, V. S., Özdemir, V., Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., KALOW, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168
Human CYP2E1 is regulated by miR-378
Mohri, T., Nakajima, M., Fukami, T., Takamiya, M., Aoki, Y., & Yokoi, T. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.015 · Cited by 170
“In addition, special attention should be paid to the fact that CYP2E1 is the most abundant isoform among all P450s in human liver (56% of total P450) at the mRNA level, followed by CYP2C9, CYP2C8 and CYP3A4 (8 - 11% of total P450) [7], whereas it is the fourth most abundant isoform (about 7% of total P450) at the prot…”
BackgroundInfluential
Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers
Kim, J. H. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.11.015 · Cited by 166
Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes
Jeong, H. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003677755 · Cited by 167
“CYP3A (CYP3A4 and CYP3A5) and CYP2C (CYP2C8, CYP2C9, CYP2C18 and CYP2C19) are the most abundant subfamilies in the liver, accounting for 30 and 20%, respectively, of the total amount of hepatic CYP [23].”
Background
CYP3A4 Polymorphisms--Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review
Keshava, C. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh294 · Cited by 166
The human drug metabolizing cytochromes P450
Wrighton, S. A., VandenBranden, M. R., & Ring, B. J. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353474 · Cited by 166
Metabolism of theophylline by cDNA‐expressed human cytochromes P‐450.
Ha, H., Chen, J., Freiburghaus, A. U., & Follath, F. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04455.x · Cited by 166
Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
Ozawa, S., Soyama, A., Saeki, M., Fukushima‐Uesaka, H., Itoda, M., Koyano, S., Sai, K., Ohno, Y., Saito, Y., & Sawada, J. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.83 · Cited by 163
Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes
Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.028 · Cited by 165
Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection
Kawakami, H., Ohtsuki, S., Kamiie, J., Suzuki, T., Abe, T., & Terasaki, T. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22255 · Cited by 168
Developmental Changes in Human Liver CYP2D6 Expression
Stevens, J. C., Marsh, S. A., Zaya, M. J., Regina, K. J., Divakaran, K., Le, M., & Hines, R. N. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021873 · Cited by 163
“Although CYP2D6 accounts for 2% or less of the hepatic cytochrome P450 content (Shimada et al., 1994), this enzyme is responsible for the oxidative metabolism of approximately 12% of clinically relevant drugs (Williams et al.”
Background
Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics
Dahl, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. S. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 163
Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents
Ginsberg, G., Hattis, D. B., Russ, A., & Sonawane, B. R. (2004) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390490273550 · Cited by 161
“For adults, this in vitro to in vivo scaling relied on the following data: (1) CYP content per milligram microsomal protein (Shimada et al., 1994): CYP1A2, 0.”
BackgroundMethodInfluential
Oxidation of Troglitazone to a Quinone-Type Metabolite Catalyzed by Cytochrome P-450 2C8 and P-450 3A4 in Human Liver Microsomes
Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14927-6 · Cited by 161
“In general, CYP3A4 has the highest content of any P-450s in human liver (Shimada et al., 1994).”
Self-citation
The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy
Mehrotra, N., Gupta, M., Kovar, A., & Meibohm, B. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901522 · Cited by 161
Pharmacology of calcineurin antagonists
Kapturczak, M., Meier‐Kriesche, H., & Kaplan, B. E. (2004) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.01.018 · Cited by 161
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor X a inhibitor
Frost, C. E., Byon, W., Song, Y. J., Wang, J. J. J., Schuster, A. E., Boyd, R. A., Zhang, D., Yu, Z., Dias, C. S., Shenker, A., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12541 · Cited by 159
CYP3A4 is a Human Microsomal Vitamin D 25-Hydroxylase
Gupta, R. P., Hollis, B. W., Patel, S. B., Patrick, K. S., & Bell, N. H. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301257 · Cited by 159
“Hepatic expression of CYP3A4 is known to vary by as much as 40-fold,((22,38)) and testosterone 6 hydroxylase activity in hepatic microsomes by as much as 31-fold,((42)) a finding very similar to the 28-fold variation in this study.”
Result
A COMPARISON OF HEPATIC CYTOCHROME P450 PROTEIN EXPRESSION BETWEEN INFANCY AND POSTINFANCY
Tateishi, T., Nakura, H., Asoh, M., Watanabe, M., Tanaka, M., Kumai, T., Takashima, S., Imaoka, S., Funae, Y., Yabusaki, Y., et al. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)01011-4 · Cited by 157
Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes
Iribarne, C., PICART, D., Dréano, Y., Bail, J. P., & Berthou, F. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00160-4 · Cited by 157
The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
Christensen, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00050-x · Cited by 157
“With regard to phase I reactions, some CYPs (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) account for more than 70% of all CYP isozymes present in the human liver and more than 90% of human drug metabolism.(12) The important polymorphic enzyme CYP2C9 has not been characterized in the Pi…”
Pulmonary Drug Metabolism, Clearance, and Absorption
Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K., Gustavsson, L., & Hegelund-Myrbäck, T. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9745-6_2 · Cited by 181
“1), whereas the major CYP enzymes in human liver are CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 [31, 69, 119, 134, 171].”
BackgroundInfluential
Changes in Antidepressant Metabolism and Dosing Across Pregnancy and Early Postpartum
Sit, D. K. Y., Perel, J. M., Helsel, J. C., & Wisner, K. L. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0419 · Cited by 156
Identification of the cytochrome P450 enzymes involved in the N‐demethylation of sildenafil
Hyland, R., Roe, E. G. H., Jones, B., & Smith, D. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.00318.x · Cited by 155
Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms*
Kim, R. B., O’Shea, D., & Wilkinson, G. R. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90227-9 · Cited by 155
Five Distinct Human Cytochromes Mediate Amitriptyline N‐DemethylationIn Vitro: Dominance of CYP 2C19 and 3A4
Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., et al. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 155
Effect of a New FunctionalCYP3A4Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant Patients
Elens, L., van Schaik, R. H., Panin, N., Meyer, M. D., Wallemacq, P. E., Lison, D., Mourad, M., & Haufroid, V. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.90 · Cited by 154
Onset of xenobiotic metabolism in children: Toxicological implications
Cresteil, T. (1998) · Food Additives & Contaminants · doi:10.1080/02652039809374614 · Cited by 154
Drug interactions between chemotherapeutic regimens and antiepileptics
Yap, K. Y., Chui, W., & Chan, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.011 · Cited by 154
Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations
Benedetti, M. S., Whomsley, R., & Baltes, E. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.447 · Cited by 155
“[106] found low, but detectable, levels of CYP2A6 immunoreactive protein and coumarin 7-hydroxylation activity in a single infant liver sample studied.”
Background
The role of natural polyphenols in cell signaling and cytoprotection against cancer development
Lewandowska, H., Kalinowska, M., Lewandowski, W., Stępkowski, T. M., & Brzóska, K. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.006 · Cited by 157
“[53] microsomes and the intestinal epithelium.”
Role of CYP2C9 polymorphism in losartan oxidation.
Yaşar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman‐Sundberg, M., Dahl, M. L., & Eliasson, E. (2001) · PubMed · Cited by 152
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 151
Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor
Köhle, C., & Bock, K. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.05.020 · Cited by 156
Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac
Chan, T. S., Yu, H., Moore, A., Khetani, S. R., & Tweedie, D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053397 · Cited by 152
Clinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150
P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer
Nedelcheva, V., & Gut, I. (1994) · Xenobiotica · doi:10.3109/00498259409038673 · Cited by 149
Thalidomide metabolism by the CYP2C subfamily.
Ando, Y., Fuse, E., & Figg, W. D. (2002) · PubMed · Cited by 150
Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
Crespi, C. L. (1995) · Advances in Drug Research · doi:10.1016/s0065-2490(05)80006-1 · Cited by 150
Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice
Veronese, M. L., Gillen, L. P., Burke, J., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003256059 · Cited by 149
Drug Interactions Between Antiretroviral Drugs and Comedicated Agents
de Maat, M. M. R., Ekhart, G. C., Huitema, A. D. R., Koks, C. H. W., Mulder, J. W., & Beijnen, J. H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00002 · Cited by 148
“In humans, CYP3A is the largest fraction of the total CYP content.[230] CYP3A4 is responsible for the metabolism of a broad spectrum of drugs, including the PIs and the NNRTIs (table I).”
Background
Human Cytochrome P450 Enzymes
Guengerich, F. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_9 · Cited by 159
Self-citation

Authors: Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P.
Affiliations: Osaka Prefectural Institute of Public Health (JP)
ORCID: Shimada, T
Yamazaki, H
Guengerich, F P
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 1994-07
Volume: 270
Issue: 1
Pages: 414-423
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1016/s0022-3565(25)22379-5
OpenAlex: W2155268095
Cited by: 2,785
References: 0
Citations by year: 2026: 14 · 2025: 28 · 2024: 24 · 2023: 40 · 2022: 36 · 2021: 55 · 2020: 41 · 2019: 59 · 2018: 52 · 2017: 53 · 2016: 75 · 2015: 81 · 2014: 121 · 2013: 104 · 2012: 118
FWCI: 64.47
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
PubMed
Funders: National Institutes of Health (5r35ca044353-14)
National Cancer Institute (CA 44353)
National Institute of Environmental Health Sciences (ES00267)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
Keywords: cytochrome P450, interindividual variability, liver microsomes, CYP1A2, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1, CYP3A4, monooxygenase activity, procarcinogen metabolism, drug metabolism, sex differences
MeSH terms: Adolescent, Adult, Aged, Aging, Biotransformation, Carcinogens, Child, Cytochrome P-450 Enzyme System, Pharmaceutical Preparations, Female, Humans, Individuality, Infant, Isoenzymes, Japan, Liver, Male, Microsomes, Liver, Middle Aged, Oxidation-Reduction, Sex Factors, Hazardous Substances, White People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks